Biomarkers of Human Longevity: State of the Market and

Diversity of Practical Applications Q4 2021

Exclusive online event

Biomarkers of Human Longevity: State of the Market and Diversity of Practical Applications Q4 2021 is an upcoming 2-day virtual conference featuring talks and panel discussions among industry leaders, companies, investors and practitioners in the rapidly growing domain of Biomarkers of Human Longevity.

 

The event is free-of-charge to attend, and will provide a stat-of-the-market overview and key company and investor take-aways for Q4 2021, highlighting key industry trends, challenges, opportunities and recent developments, and explore the rapidly growing diversity of market-ready, practical applications within the industry.

 

Organized by the Aging Analytics Agency, the Longevity-focused analytical subsidiary of Deep Knowledge Group, which currently serves as an Official Member Organization of the United Nations NGO Committee on Ageing, a Supporting Partner of the UK All-Party Parliamentary Group (APPG) for Longevity, and a Founding Member of the APPG for Longevity Secretariat, Longevity International. 

Agenda
One Pager
Teaser
Biomarkers of Human Longevity Conference (1920х1080).png

Speakers

Afshin2.png

Dr. Afshin Beheshti

KBR at NASA Ames Research Center

Dr. Beheshti completed his PhD from Florida State University in physics and made a transition to cancer, systems biology, and radiation biology for his postdoctoral training. In 2014 he became an Assistant Professor at Tufts University School of Medicine/Tufts Medical Center where he continued his research as a systems biologist studying various aspects of cancer including microRNAs, aging and cancer, cancer drug targets, and development of novel immunotherapy. 

In April 2017, Dr. Beheshti joined KBR, NASA Ames Research Center to be part of the GeneLab project assisting with developing the platform. In addition, Dr. Beheshti also has obtained his own grants where he is conducting research on how microRNAs will affect space biology and potential use for countermeasures to mitigate space radiation and microgravity. Lastly, Dr. Beheshti currently also holds a Visiting Researcher appointment at Broad Institute of MIT and Harvard and is the Lead of a non-profit formed on March 2020 working on COVID-19 called COVID-19 International Research Team.

Fedor2_edited.jpg

Fëdor Galkin

Director of Scientific BD at Deep Longevity

Fёdor Galkin was working with Insilico Medicine since 2018 and in  2020 transferred to its spin-off Deep Longevity — a Hong Kong startup focused on digital solutions for longevity medicine. He is conducting research on biomarkers of aging and developing commercial products for use in clinics, insurance, and consumer applications (Young.AI).

Jeremy_500x500.jpg

Jeremy Malecha

CEO and co-Founder of Biocanic Inc. 

Jeremy Malecha is CEO and co-founder of Biocanic with over 20 years of medical and software related experience. Prior to Biocanic, he was the Vice President of M&A Strategy in ResMed’s SaaS Business. Jeremy holds a Bachelor of Engineering in Biomedical Engineering from Northwestern University

1587699159364.jpeg

Jin-Xiong She

Founder and CEO, Jinfiniti Precision Medicine

Jin-Xiong She, PhD received his college education in China and PhD degree in France.  After a short postdoctoral training, he was quickly promoted to Assistant Professor, Associate Professor, Full and Endowed Professor at the University of Florida (UF).  He served as Division Chief of Experimental Pathology and Director of Research of the UF’s Diabetes Center.  Dr. She was recruited in 2002 to be a Georgia Research Alliance Eminent Scholar in Genomic Medicine at the Medical College of Georgia and the founding Director of the Center for Biotechnology and Genomic Medicine.  He was Professor at the Department of Pathology, Department of Obstetrics and Gynecology as well as the director of two core research facilities (Genomics, and Proteomics & Mass Spectrometry) for Augusta University. In his academic career, he has authored over 350-peer reviewed papers with an H-Index of 68 and over 15,000 citations, secured over $100 million in research grants, invited to speak globally.  He mentored 13 doctoral students, 47 post-docs and 12 faculty. Dr. She is one of the top 20 “Georgia Top Medical Researchers” named by the Atlanta Business Chronicle.  He served as President of the Chinese Geneticists in America and President of the American Diabetes Association’s council on Immunology, transplantation and Immunogenetics among other honors.  Dr. She is a serial entrepreneur and has founded or co-founded six companies, the latest of which is Jinfiniti Precision Medicine, Inc. that aims to provide an end-to-end solution for healthy longevity via biomarker testing and personalized management of nutrition and nutraceuticals.

Gordon Luac.jpeg

Professor Gordan Luac

Director of Human Glycome Project

Gordan Lauc is the Professor of Biochemistry and Molecular Biology at the University of Zagreb, Director of the National Centre of Scientific Excellence in Personalised Healthcare, honorary professor at the University of Edinburgh and the Kings College London and member of the Johns Hopkins Society of Scholars. In 2017 he initiated the launch of the Human Glycome project and is one of its two co-directors. His research team is pioneering high throughput glycomic analysis and the application of glycan biomarkers in the field of precision medicine. By combining glycomic data with extensive genetic, epigenetic, biochemical and physiological data in a systems biology approach they are trying to understand the role of glycans in normal physiology and disease. Professor Lauc co-authored over 200 research articles that are cited over 5,000 times. In 2007 he founded Genos, a biotech company that is currently global leader in high-throughput glycomics. Research in Genos led to the development of the GlycanAge test of biological age.

ryan-headshot.jpg

Ryan Smith

Founder of TruDiagnostic

Ryan Smith attended Transylvania University and graduated with a degree in Biochemistry. After finishing all the educational curriculum and passing USMLE Step 1 he decided to leave and open up a pharmacy in the United States that focused on peptide synthesis and formulations for pharmaceutical preparations. That pharmacy, Tailor Made Compounding, became the 4th fastest growing company in healthcare in the US. Ryan exited Tailor Made in late 2020. Since then, Ryan has opened many businesses including TruDiagnostic, a company focusing on methylation array-based diagnostics for life extension and preventive healthcare. TruDiagnostic is a CLIA certified lab and health data company focused on serving integrative and functional medicine providers in the United States. TruDiagnostic has a commitment to research with over 21 approved clinical research studies investigating the epigenetic methylation changes of a variety of longevity and health interventions. Since Tru Diagnostics inception, they have created one of the largest private epigenetic health databases in the world with over 13,000 patients tested.

Franco2.png

Franco Cortese

Director of Aging Analytics Agency

Franco Cortese is Director of Aging Analytics Agency, and has been a member of the company’s executive management team since its inception. He is one of the co-creators of the Longevity Industry Framework behind many of the company’s Longevity Industry analytics, benchmarking and forecasting.

 

He is also one of five co-authors behind the proposal that led to the World Health Organization's addition of a new extension code for aging-related diseases (XT9T) during ICD-11, and the author of over a dozen scientific papers in peer-reviewed journals such as:
- Scientific Reports (Nature Publishing Group),
- Experimental Gerontology, Aging,
- The Journals of Gerontology Series A: Biological Sciences and Medical Sciences (Oxford Academic),
- Sleep (Oxford Academic),
- Human Gene Therapy,
- Frontiers in Genetics,
- Rejuvenation Research,
- Oncotarget,
- Translational Neurodegeneration.

Dmitry Kaminskiy.png

Dmitry Kaminskiy

General Partner of Deep Knowledge Group

Dmitry Kaminskiy is an innovative entrepreneur, investor, author and philanthropist dedicated to impact investment and ethical business, with a focus on engineering the accelerated trajectory of progressive technological development for the benefit of humanity.Mr. Kaminskiy is a co-founder and managing partner of Deep Knowledge Group - a consortium of commercial and non-profit organizations active on many fronts in the realm of DeepTech and Frontier Technologies (AI, Longevity, Precision Medicine, FinTech, GovTech, InvestTech), ranging from scientific research to investment, entrepreneurship, analytics, policy and philanthropy.

 

He leads the activities of the consortium’s venture arms - Deep Knowledge Ventures, an investment fund focused on DeepTech and advanced science projects, and Longevity.Capital, which prioritizes the convergence of Longevity and Artificial Intelligence, areas in which it has unparalleled investment and exit strategies.

Previous Events

“Longevity.International presents: Biomarkers Of Human Longevity” was a virtual 1-day conference that took place June 30, 2021 featuring presentations from a variety of companies, key players and thought-leaders active within the Biomarkers of Human Aging and Longevity Industry.

 

The event explored the present state of the industry, as well as key strategic challenges and opportunities for translating the potentials of Biomarkers of Human Longevity from theory into practice.

"Practical Applications of Mitochondria Research for Human Longevity and Space Medicine" was a virtual conference that took place June 9-10, 2021, where professionals from Aging Analytics Agency and guest speakers who are Practical Longevity Experts, Space Medicine Experts and Women Influencers shared insights, findings and personal experiences about the Role of Mitochondria in The Practical Human Longevity and Scientific Approaches to Women For Extending Reproductive Longevity.